DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
Key Financial Performance
Revenue $5 million, which was lower year-over-year and quarter-over-quarter. The decline reflects the non-renewal of a large scope of work with a national health plan in early 2025 and a deliberate shift from one-time revenue streams towards long-term annual recurring revenue.
GAAP Gross Margin 60%, up from 55% in Q2 2025 and 52% in Q3 2024. This improvement is attributed to the benefits of a software-led model and disciplined cost management.
Non-GAAP Gross Margin (B2B2C) Above 80% for seven consecutive quarters since the beginning of 2024, reflecting the benefits of a software-first model.
Operating Expenses Reduced by $17.2 million or 31% in the first 9 months of 2025, and by $3.4 million or 21% during Q3 2025 compared to the year-ago period. This reduction was driven by post-merger integration, process automation, organizational streamlining, and expanded use of AI-based workflows.
Operating Loss Improved by $18 million or 39% for the 9-month period compared to the previous year.
Cash and Equivalents $31.9 million as of September 30, 2025, reflecting a $17.5 million private placement of common stock and equivalents.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Multi-condition digital health platform: DarioHealth's platform integrates physical, mental, and behavioral care, addressing conditions like diabetes, hypertension, weight management, musculoskeletal pain, and mental health. Over 50% of new clients in 2025 chose this solution.
AI-powered personalized engine: The platform uses AI to combine biometric, self-reported, and behavioral data, delivering measurable outcomes and driving high gross margins (60% GAAP, 80%+ non-GAAP).
New product partnerships: Dario integrated OneStep's AI-powered fall risk assessment technology, enhancing ROI for health plans by reducing avoidable claims and improving safety.
Client base expansion: Dario now serves over 125 clients, including 4 national and 7 major regional health plans, and numerous Fortune-level employers, reaching over 116 million covered lives.
New health plan launches: UnitedHealthcare launched Dario on its digital marketplace, with a full national rollout planned for January 2026. Premera Blue Cross and Florida Blue also launched Dario through partnerships.
Public sector opportunities: Dario is exploring federal and state-funded health programs, leveraging its pricing and clinical benefits to compete in this space.
Revenue model transition: Shifted from one-time revenue streams to high-margin annual recurring revenue, targeting $12.4 million in new business for 2026.
Cost reductions: Reduced operating expenses by $17.2 million (31%) in the first 9 months of 2025, with further reductions expected.
Financial position: Completed a $17.5 million private placement, simplified capital structure, and improved operating loss by $18 million (39%) year-over-year.
Channel partnerships: Strengthened partnerships with Solera Health, Aetna, and Amwell, expanding market access and accelerating deal closures.
Pharma services growth: Transitioned to a recurring revenue model, focusing on therapeutic areas like MASH, delivering significant ROI for pharma clients.
Special committee engagement: Dario engaged Perella Weinberg Partners to explore strategic opportunities following unsolicited expressions of interest.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for the third quarter of 2025 was $5 million, down from $7.4 million in the third quarter of 2024. This decline reflects the non-renewal of a large scope of work with a national health plan in early 2025 and the shift from one-time revenue streams to long-term recurring revenue.
Client Retention Risk: The company has set an internal benchmark to retain roughly 85% of its clients year-over-year, but achieving this target is critical to maintaining revenue stability.
Pipeline Conversion Uncertainty: The company is targeting $12.4 million in new business for 2026, but a portion of this is still in late-stage development, creating uncertainty in achieving these targets.
Economic and Market Conditions: Policy tailwinds and rising healthcare costs are driving demand for digital health solutions, but economic uncertainties could impact client budgets and adoption rates.
Operational Efficiency Challenges: While operating expenses have been reduced significantly, further reductions of 10%-15% are planned, which may strain resources and impact operational capabilities.
Regulatory and Competitive Pressures: The company operates in a highly regulated and competitive digital health market, which could impact its ability to scale and maintain margins.
Dependence on Channel Partners: Over 80% of new logo wins come from channel partners, creating dependency on these relationships for growth and market access.
Capital Structure and Financial Resilience: The company has simplified its capital structure and raised $17.5 million, but financial resilience remains critical as it aims for cash flow breakeven by late 2026 to early 2027.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue expectations: The company is targeting $12.4 million in new business for implementation in 2026, including committed annual recurring revenues and late-stage pipeline opportunities nearing completion. Revenue momentum is expected to grow in 2026, supported by new accounts and a $69 million pipeline.
Profitability and cash flow: DarioHealth expects to reach cash flow breakeven by late 2026 to early 2027. Operating expenses are projected to decline by an additional 10% to 15% over the next 12 to 15 months, contributing to profitability.
Market trends and business segment performance: The company anticipates strong demand for its multi-condition digital health platform, with a growing preference for integrated solutions among employers and health plans. The average employer account size has nearly doubled compared to the previous year, and the company is seeing significant traction in the public sector and pharma business.
Client and account growth: DarioHealth has signed 45 new accounts year-to-date in 2025, surpassing its goal of 40. The company expects continued client growth, with several large health plans and employers onboarding in 2026. Client retention remains strong at 90%.
Strategic partnerships and launches: Key partnerships include UnitedHealthcare, Premera Blue Cross, Aetna, and Florida Blue, with major launches planned for 2026. These partnerships are expected to expand market access and accelerate growth.
Operational efficiency: The company has reduced operating expenses by $17.2 million (31%) in the first nine months of 2025 and plans further reductions through automation and AI-based workflows.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you help us understand how much of the $12 million in new business expected to be implemented in '26 is coming from UnitedHealth?
A:Steven Nelson explained that UnitedHealth is rolling out a digital marketplace for their book of business in chunks, starting formally on January 1, 2026. However, he did not provide specific revenue details by client or segment but expressed optimism about the opportunity.
Q:Can you help us understand what sort of pacing we should be modeling in and expecting for this new business?
A:Steven Nelson stated that some accounts have already started in Q4, with the majority rolling in during Q1 2026. Some accounts may start slightly later due to off-cycle enrollments or government budget delays. He emphasized that most of the $12 million will be realized in Q1, with some tailing into later periods.
Q:Can you help us understand what's driving the sequential declines in B2B2C revenue despite a 90% renewal rate?
A:Erez Raphael attributed the decline to a non-renewal of a national health plan in early 2025 and the transition of the pharma business from milestone-driven to recurring revenue. He noted that employer and health plan business remained stable and is expected to grow slightly in Q4.
Q:Can you give us an update on the pharma services pipeline and how prospective clients are responding to the sharper focus on therapeutic areas?
A:Erez Raphael stated that the company is prioritizing employers and health plans over pharma. They have shifted to a SaaS-oriented model, focusing on recurring revenue and being selective with pharma accounts. He expects 2-4 pharma accounts to contribute revenue next year, but the numbers will be smaller compared to other channels.
Q:What are you finding is working better now compared to 12 months ago in terms of product market fit and the new performance-based pricing model?
A:Steven Nelson highlighted improvements in claims-based analytics and engagement, partnerships like GreenKey for sleep and OneStep for fall prevention, and a more targeted approach to client acquisition. These changes have enhanced product market fit and reduced R&D costs.
Q:Does working with federal and state governments present unique challenges compared to the commercial side?
A:Steven Nelson stated that government initiatives align well with their offerings, particularly value-based payment models. Challenges mainly involve government budget appropriations, but he expressed optimism about opportunities in maternal and rural health initiatives.
Q:Has anything changed in your approach for go-to-market that led to 45 new client wins this year?
A:Steven Nelson attributed the success to doubling down on channel partners, targeting specific client segments, and leveraging new partnerships like TPA and PBM relationships. He emphasized a differentiated and deliberate strategy.
Q:Why has the percentage of clients taking multi-condition offerings dropped from 80% to 50%?
A:Steven Nelson explained that the drop is due to some channel partners initially offering only single-condition solutions. He remains confident in upselling and cross-selling multi-condition offerings, noting that 50% is still a strong figure.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue details for UnitedHealth's contribution to the $12 million in new business for 2026, citing a lack of disclosure on client-specific revenue segmentation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aetna employer
Blue Cross
Florida Blue
Fortune
GreenKey Health
MASH
Pharma Services
Premera Blue
President
Temple
Thursday
agreement
base
channel partner
confidence market
credit
economics
health insurer
history
launch
margin model
market opportunity
month period
number
opportunity completion
partner Florida
partner life
period improvement
person
result event
sector
software model
stage opportunity
stock equivalent
strength
validation platform
DRIO Transcript
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a focus on future growth and profitability, with expected revenue contributions from 2025 accounts and a path to breakeven by mid-2027. However, the lack of specific financial figures and uncertainty in achieving these milestones pose risks. No new partnerships or strong financial metrics were highlighted, and there was no mention of shareholder returns. Without clear guidance or immediate catalysts, the stock is likely to remain stable, resulting in a neutral prediction.
Sylogist Ltd. (SYZ:CA) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents mixed signals: while there are positive elements like improved recurring revenue gross margins and strategic partnerships, there are concerns about project service margins turning negative and soft SaaS ARR bookings due to timing issues. The Q&A reveals uncertainties about growth and margin progression, with management avoiding specific timelines. Despite a strong pipeline and transformational efforts, the lack of concrete guidance and ongoing transition phase temper overall optimism, suggesting a neutral stock price movement in the short term.
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
Positive3-19
Despite a revenue decline due to a legacy client nonrenewal, the company shows strong operational efficiency with reduced expenses and improved margins. Strategic partnerships with major health plans and a growing pipeline indicate future growth potential. The Q&A session highlighted confidence in meeting analyst expectations and achieving cash flow positivity. The company's proactive cost management and strategic partnerships are positive indicators, despite economic uncertainties and competitive pressures. Overall, these factors suggest a positive sentiment towards stock performance in the short term.
DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
DRIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
